ACR 2026: RA Topic Panel Save
What stood out in rheumatoid arthritis at ACR 2026? Join Drs. Jon Kay, Jack Cush and Artie Kavanaugh for RheumNow’s RA Topic Panel Recap. They discuss the research that caught their attention in Orlando and what the findings could mean for the everyday care of patients with RA.
Transcription
This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.
Go to roomnow.live to see the full program and register today. Hello, everyone. This is RheumNow, and we're gonna do a panel discussion on rheumatoid arthritis covering items of interest and conversation from ACR convergence twenty twenty seven. I'm Jack Cush with RheumNow in Dallas, Texas. I'm joined by John Kay at UMass and Artie Cavanaugh at UCSD.
Gentlemen, thank you for joining us. Our format's gonna be a little bit different on this panel. We're gonna do our own little topic themes and then do some discussion. John, why don't you start us off?
Thanks, Jack. It's great to be here and be with you and Arti. I'm gonna talk about cell based therapy. That's a hot topic, especially starting with lupus. Much of the discussion with lupus is all about CAR T cells, and T cell engagers.
I'm going to talk about two abstracts, Abstract nineteen oh two and two thousand three and eighty four. So Abstract nineteen oh two was an oral presentation delivered by Professor David Simon from the Charite in Berlin about the COMPARE trial, a phase one study in which there was a single infusion of CD19 directed CAR T cells in six patients with what was called highly treatment refractory ACPA positive rheumatoid arthritis or difficult to treat rheumatoid arthritis. These patients had had longstanding active disease with a median of six and a half biologic or targeted synthetic DMARDs, and after discontinuation of DMARDs and glucocorticoids, lymphodepletion, and CAR T cell infusion, all six patients experienced clinical improvement, and three maintained drug free remission over the course of the year through week fifty two. The investigators reported quote unquote manageable short term toxicity. All patients developed grade one or two cytokine release syndrome that resolved within three to five days.
No neurotoxicity and no severe infections. Cytopenias were common, and one patient experienced grade three transaminase elevation. The patients experienced profound depletion of CD19 positive B cells in peripheral blood, bone marrow, and synovial tissue that was accompanied by a marked reduction in rheumatoid factor and ACPA with loss of rheumatoid factor and ACPA in four of the six patients. The reduction was 92 to 96% by week fifty two. When B cells reconstituted, the B cells that recovered were predominantly naive and transitional B cells, and there was substantial depletion of memory B cells and plasmablasts.
Antigen experienced TCP reactive B cells were eliminated in all three patients in which this was evaluated, suggesting that disease related autoantibodies are depleted, and the clinical improvement was corroborated by reductions in synovial inflammation by ultrasound, and they also looked at fibroblast activation on FAPI PET imaging. So the conclusions were that CD19 CAR T cell therapy can induce profound immunologic remodeling, perhaps resetting B cell immunity and achieving sustained drug free remission in some patients, but not all. So the responses in this study were heterogeneous, just like in the T cell engagers where patients with rheumatoid arthritis, unlike those with lupus, experience a reduction in disease activity over the first several months, but some experience a recurrence of disease activity that requires use of biologic medications such as abatacept to control disease. Now, some of these patients had previously been unresponsive to the medication that then is used to maintain control of disease. So this is sort of a resetting but not a drug free control inducing therapy.
They planned a randomized phase two comparison with rituximab to see if this is better than rituximab or equivalent. So that is Abstract nineteen oh two about CD19 CAR T cell therapy in highly refractive rheumatoid arthritis. The other abstract is an abstract that was supposedly withdrawn but not withdrawn and was presented. This is Abstract two thousand three and eighty four, which was from Arteva, which just before the ACR meeting announced that they were discontinuing development of their AlloNK therapy. They presented this AlloNK therapy AB101 at EULAR as a late breaker, and it was very positive in terms of their results with rheumatoid arthritis, Sjogren's, and systemic sclerosis.
They experienced improvement in disease activity in the patients treated. Now, this is an off the shelf ALLO NK cell that is derived from cord blood, and the Fc receptor on this ALONK cell is then bound to an antibody, in this case rituximab, and with the rituximab and the ALONK, it depletes B cells. So they experienced profound B cell depletion with B cell reconstitution beginning about six to twelve months after treatment, and like with the CD19 CAR T cell, it was characterized predominantly by naive and transitional B cells. They experienced preservation of serum immunoglobulin concentrations and vaccine antibody titers, so it sounded really good, except they had one patient with Sjogren's disease who developed a fatal grade five leucoencephalopathy approximately ten weeks after treatment with MRI findings that suggested fludarabine associated neurotoxicity, but they can't rule out multifocal progressive leukoencephalopathy, which has been observed with rituximab as well. So, this drug, while potentially effective, was killed by that death experienced in this clinical trial.
So, rituximab with this off the shelf ALONK cell was effective, but the toxicity profile suggested that it wasn't going to be developed further. Now, Novartis and BMS also stopped their CAR T cell programs because of significant toxicity. So, while potentially very effective, the potential toxicity of this cell based therapy approach is not clearly going to be successful for a disease like rheumatoid arthritis, where you can't afford to have severe fatal, reactions.
So there are sort of two, a few messages here that are consistent. One, gee, it's a win, but wait, it's not, But both of them are calling into question the idea of B cell depletion as a therapy in rheumatoid arthritis. I only look at our rheumatology community, how much are you using rituximab by the way? You know? And again, we have a lot of other choices and that's why we don't use a lot of rituximab, but I think some people aren't impressed with rituximab and, you know, we did the clinical trials, we know the drug does work.
It's fine to be where it is, but I think that these studies which have really profound depletion of B cells, have some shortcomings. And that makes me wonder about whether we should be looking forward to cellular targeting therapies in rheumatoid arthritis.
Also from rituximab, and there were a couple of abstracts that really, I think, speak to this issue, the risk benefit. One, 1901 is from Leeds. And remember in Leeds, they've been big proponents of looking at very highly sensitive flow cytometry. Remember, everyone you treat with rituximab depletes their peripheral B cells. But the issue is we're not depleting B cells in the lymphoid organs.
And they would say we're not really completely destroying the peripheral B cells and the plasmablasts, with the treatment. And if what they did is they looked at baseline levels of depletion. And what they found is that the better you depleted, the better you did at five years. So this is treatments and then looking five years later. And the more completely you depleted just with rituximab.
And those who depleted better did better later on. And on the other end, of bookends of this is abstract 2,831. This is from China. And this looked at rituximab in rheumatoid arthritis in the clinic. They had 70 patients, but they had almost 19 infusions each.
And so over time, over the long period of follow-up, which was almost nine years, they have a linear decline in IgG, which you perhaps would have expected. But the strongest association with serious infectious events was low IgG, beyond steroids, beyond comorbid conditions. So yes, the better you deplete, the better you do, but you gotta be careful.
Yeah. So, John, you you looked at that compare trial, was the CAR T... C d nineteen CAR T. When we looked at that, I I was a little concerned about autoantibodies came down, but they came down variably, and responses, you know, were kinda slow whatnot. Maybe they're not getting full depletion.
Again, you're just measuring blood B cell populations. We don't know what's going on in tissues and plasmablasts and whatnot, but what's your take on the clinical responses in those trials?
Well, those trials, the clinical response is good initially, just like you see with biologic or targeted synthetic DMARDs, but the durability of that clinical response by itself is not all that long lasting. The depletion of the autoantibodies, as you point out, reflects what's going on in peripheral blood. They saw deep depletion when they looked at synovial biopsies. But even with deep depletion in the synovium, the durability of response isn't that long. And this is very similar to what Ricardo Grieshopper Boyer observed in the T cell engagers that were published in Nature Medicine out of Erlangen, where there was an initial decrease in disease activity, but then those patients pretty much required some sort of biologic or targeted synthetic DMARC to maintain control of disease.
So these therapies are relatively rapid acting, but not great durability.
So let me just interject another one here that's kind of along the same theme that we're on, and that was, abstract, 09/18 when Professor Pizzalis and his coworkers talked about, synovial biopsies in early RA and looking at five year outcomes. That seventy five patients with early RA who had at least twelve months of follow-up, and looked at them five years later, and they stratified the patients on what they did over the five years, either they were in remission or low disease activity or they were in moderate or high disease activity, forty five and thirty patients respectively. But at baseline, when they did the histology cellular types, it was very clear that the people who did bad had a lot of overexpression of immunoglobulin and humoral immunity, even though these people had early disease. The people who, did the best were in remission or LDA seemed to have more fibroblasts and tissue remodeling markers. The interesting thing to me about that is those are things that we don't target in early disease.
We tend to leave rituximab to, you know, late stage, you know, you know, crashes. And people that, you know, we just have tried as was the case in the COMPARE trial, they had failed six prior DMARDs and biologics at least. So, you know, maybe this this work by Constantine is going to help redesign some of the approach at least to early RA.
Does that Jack, he has a poster every meeting. I love the guy, he's a big proponent of synovial biopsies, it makes total sense that it should be helpful. But these means of gathering data are so robust. You get so much data that you're going to have a story. You're going to absolutely have a story of significance.
And what you do with that, and these conclusions are a little bit different than he had presented previously. His R4RA study looking at synovial biopsies and then trying to say, could you guide therapy toward T cell directed or B cell directed? A word of caution, I think.
I'm sorry, John, maybe we need AI to analyze. What you're right is incredibly, robust, meaning lots of data from which you have to build the story. I like the caution, but I also like the prospective excitement. John?
Well, it's interesting that Koss has also shown that in the difficult to treat rheumatoid arthritis patients, there's a predominance of the fibroblast pathotype. So it's interesting here that early RA, you see a fibroblast predominance that's not addressed in later on. So the drugs that are being developed now, like antibodies to TL1A, address targets that are expressed on fibroblasts. So that's suggesting that the direction of drug therapy really should go, toward the fibroblast, which is really the unmet need in rheumatoid arthritis.
Amen. Amen. Artie, you had, two that excited you.
Well, there's a couple of things. One, the story of clinically suspect arthralgia. We seem to revisit this, at most meetings over the past few years anyway, and it's an important clinical problem. We see these people all the time, don't we? Now that we have gotten our primary care providers and even ER doctors used the idea of checking CCP antibodies, particularly in addition to rheumatoid factor.
You have patients who show up in the clinic whose joints hurt, you don't think that they have synovitis, maybe even look at highly sensitive imaging like ultrasound and MR, and they don't have synovitis, but we know some of them, twenty five-thirty percent of them will go on to develop rheumatoid arthritis. So how do we find those people? Could we possibly treat them that, may end up preventing or at least delaying or perhaps attenuating the rheumatoid arthritis that they develop? Important questions. We still don't have, an absolute answer.
But there are a couple of nice abstracts that looked at this. One was 1832, and I think this should be a teaching slide in, all of our collections. This looked at the military, repository. And of course, when you join the military, you have samples taken of your blood, at various time points. So you have some of the people in the military developed rheumatoid arthritis, and then you can go back and say, at what point did they see or convert?
Did they develop rheumatoid factor and CCP? And as we had seen previously in very similar studies from a similar database, the ANA, here too, we see that the CCP and the rheumatoid factor are start to elevate years before the diagnosis. So, there's something there and that fits with the thing we always say. It's a genetically susceptible host exposed to some, environmental or other influence that then develops the ongoing dynamic, auto inflammatory rheumatoid arthritis. But we just don't know who.
Another abstract, the 1837 looked at what the UR ACR risk stratification. And it's the things that we see in the clinic, including actual morning stiffness, which, you know, your fibro patients are stiff twenty four hours a day, which is not impossible because they're asleep. Grip strength, which we stopped doing, the, swelling and the autoantibodies. And The model is good, but we're still not up to the point where we can use that to say that know which of those patients is going to develop rheumatoid arthritis. Then a follow-up abstract 95, maybe one of the saddest abstracts or saddest bits of research ever because I think we were all hoping it would work and that's the STOP RA study.
Remember that was treating patients who are these clinically suspect arthralgia patients but are CCP positive, treating them with hydroxychloroquine. And as you recall, there was absolutely no difference in the development of rheumatoid arthritis. You could not make a case. You couldn't have cheated and drawn those lines on top of each other any better. So it really had no effect, which was I think incredibly disappointing.
I think we would have loved if a safe medicine like hydroxychloroquine had had some benefit, but this showed that it didn't. This is just a follow-up, actually not new information, but that rheumatoid factor. So remember they had to be CCP positive to get in. But if you throw in rheumatoid factor that really increases the odds that they're going to develop rheumatoid arthritis. But is it enough to actually say that next person you see in clinic tomorrow that you're going to act upon that remembering all the old studies that we have had with abatacept quite a number of studies with rituximab with methotrexate had to stop RA with hydroxychloroquine.
Still an important topic and still unresolved.
Arty, you bring up some very interesting points. That study from the US military serum repository, I recall that they also identified antibodies to PAD one and PAD four, which are peptidyl arginine deaminase. PAD four is involved in citrullination as is PAD one. PAD two is involved in the generation of TNF. So it's interesting that they're also developing antibodies against the enzyme that's involved in citrullination.
I don't know what that means, but interesting. The other point that you bring up about the EULAR criteria with measuring grip strength, those are sort of an expansion of the CARE tool, which was developed in Leiden by Annette Vanderhelm Van Miele, where they came up with a score, I think seven questions and a score of four was the cutoff, that suggested that patients had high likelihood of progressing to early inflammatory arthritis. Not to be self serving, but I'd like to point out my colleague, Karen Salomon Escoto, who had a poster at EULAR where she validated the CARE tool in The United States and came up with exactly the same cutoff of four. So that could be used to prioritize patients who have clinically significant arthralgia to give them an earlier appointment than they would normally get since rheumatology clinic schedules are quite full and enhance the ability of those patients to be seen early and initiated on appropriate therapy. And at this meeting, Abstract fourteen forty six, Karen presented the use of Squeeze Egg, Squeg, which is a device that's commercially available, costs about $100 It's Bluetooth enabled and FDA approved to measure grip strength.
And it transmits the grip strength to an app on the iPhone, and you can record it in the clinic note. And so there's a way of measuring the grip strength other than just pumping up a sphygomanometer slightly. And it's quite useful to detect deteriorations in how a patient is doing in between visits if they do this remotely or between visits if you do it when you see the patient.
Yeah, in RheumNow, I think this is called a mulligan, Jonathan, when you reference your own work. So you get one, so you took it nicely done, nicely played.
I like it. Autoantibody chronology and the slide of that where it grows really over twenty years, not even ten, It is still spearheaded by CCP. CCP is the earliest, the strongest and whatnot. As you get closer and closer to time point zero when they develop RA is when they get this greater multiplicity. To me, reinforces that model of autoimmunity starts, there's epitope spreading, there's this multiplicity of autoantibodies.
It is many autoantibodies at the time of disease onset, and we know that having multiple autoantibodies is itself a risk factor. Now, don't know if it's a chicken or the egg there, that the antibodies themselves are the causative factor or what's driving autoantibodies, but it really conforms very well to the story and like Hardy says, it becomes a great teaching tool. Then the other thing I'd say about UR score is that it validates and the score of your colleague, John, validates what Kevin Dean said a long time ago. Is it CSA and you just got to watch it or is it RA and you need to treat it? And it's a ratcheting effect.
The more things they've got that make you think, oh, this is looking more and more like RA beyond the CCP and a positive family history, the more you can step in and, you know, give me your best shot and, play Pat Benatar over and over again, maybe with the hope of helping some. But we do have data on on what we should use and when we should use it. But
still So, Jack, along those lines, because I find to the patients, the CSA patients, it's a hard sell to offer the medicines for disease they may never develop. But I bet you, and I haven't really done this yet, but I might have to, is that they're open to turmeric. They're open to Mediterranean diet. They're open to weight loss. Maybe that's the time, at that time...
Maybe you can still influence the disease, and the way to do it is not by medicines, but by lifestyle.
So it's basically, it's fad, DTC and television, and fear are the motivating factors as to whether or not they might want a therapy. Let me move on because we want to wrap this up. There was a plenary session that was, I think, interesting. It was a small study out of Duke. Hannah McClellan and colleagues abstract twenty eight zero three immunologic and clinical benefits of lifestyle, remodeling on an aging immune system in RA.
They took 20 RA patients, and they did this pilot trial where they were, sedentary, at least overweight, if not obese. BMIs of twenty eight to forty, and they either were randomized. Everyone got some sort of counseling. And then the... And and the sweat group, the SWET group got intensive, exercise training and lifestyle counseling more than the chat observation group.
And when they looked at them, I think the time point was twelve or sixteen weeks later that, yes, both groups got better with improvement in their DAS CRP, which improved by fourteen percent and patient global swollen joints improved by thirty six percent. But the sweat group, the, lifestyle intervention with diet and exercise, exercise being a 115 week. They found out it was actually even less that that was even effective. They had cellular changes with significant changes in Tregs, NK cells, memory t four cells that were interesting. And while that was going on, the patient also had improvement in strength and mobility and function.
But what didn't improve was cytokine profiles, sed rate and CRP. You'd think this bland population of older people who are obese, and that what am I gonna do for them? This kind of research suggests that, lifestyle changes can do a lot for them and I found that surprising. I really thought that, I'd like to see where they go with this. That might be even more interesting.
The other thing that kinda fits in with lifestyle was another plenary from, presented by Nicholas McCormack, representing the RISE registry. This is abstract o eight six seven showing that when GLP-one, agents were used in RA and PSA, and they specifically looked at patients starting semaglutide and tirzepatide, that they had significant weight loss. I think it was like 15 pounds. In general, 15.6 pounds, and 58, 54% loss greater than 5% of their body weight. We know from psoriasis studies that losing at least 5% will give you clinical benefits.
10 of 10% great benefits. 20% wow. But that this drop in weight was associated with a drop in rapid three scores. For every, I think, 5%, you drop your rapid three by, like, one point or whatever. So it was kind of a positive report about GLP one and inflammatory arthritis, RANPSA.
But it was kind of on the mild side because an abstract presented effort was the study that, Philip Conahan presented that was just dramatic. You know, these people had lost 71 pounds and had dramatic improvement, clinically. So the question is, do you need to lose more weight? Is or maybe RA isn't the great subject here for, triple agonist interventions with incretin therapy as it is in PSA and in OA. I think that those two abstracts were very contrasting.
John, I know you want to talk about this. What's your thought?
It was interesting that in that abstract from the RISE registry, after the presentation, there was a question about swollen and tender joints, and there was no significant improvement in swollen or tender joint count, which doesn't quite support the efficacy of GLP-one therapy in rheumatoid arthritis. There were a whole bunch of TriNetX analyses where someone can just call up the data in an hour, get an abstract, which one suggested that PSA was better than RA for GLP one response. There's no question that weight loss is beneficial and exercise is beneficial. John Varga mentioned he thinks that aging is the key to all rheumatologic diseases. So looking at the biology of aging, maybe advanced glycation end product formation, which plays a role in a number of processes in collagen.
Getting back to GLP-1s, certainly they're beneficial in many, many, many ways. Anti inflammatory effects are just but one. They act on the central nervous system. Anecdotally, I've found that my patients who are on GLP-one therapy are more pleasant and easier to deal with once they're on them. They seem happier.
So other than the cost, there seems to be little downside, the rare eye complications. But it looks as if probably a third of the population is taking these and the other two third would if they could afford them.
Old joke, the, guy goes... They said, boy, what's up? Said, well, I went to the doctor. He said, you know, you eat less, don't drink, don't smoke, don't chase women, start exercising, lose weight, and you live an extra year. Said, So I did it.
It was the most miserable year of my life.
Exactly.
Well, know what? I want to end this session with a story And, many of you know and some of you look forward to the end of every ACR where Artie Cavanaugh and I, do Rheumatology Roundup. And we've been doing that for about twenty years, but the originator of Rheumatology Roundup was Jonathan Kay. John, how did you get us on the map with this gig?
I was chair of education at the time, and we were discussing how best to end the meeting, and we were inspired by CARTAL, click and clack. And we found that the... Or felt that the rapport between you and Arty was similar to that between Tom and Ray Maliatsi. And we suggested this as a session based on a tape that was sent in, and it was incredibly successful. And it persisted for a number of years.
Although, this year, I just tuned into the RoomNow podcast and heard the beginning of an hour long discussion between you and Artie doing a a version of that rheumatology roundup, which wasn't at the meeting, but is immortalized for all of us to listen to during our commute.
Yeah. The ACR decided to go a different way about five years ago, but there are still people that are stopping Arty and I on the last day and saying, I'm coming to your session. What time does it begin? And it's sort of like, well, you're gonna have to tune in on your podcast channel. So anyway, I wanna thank Arty and John for a great discussion and covering, what is always an interesting area at ACR, rheumatoid arthritis.
Tune in for more topic panels. Bye, everyone. Bye bye.
Go to roomnow.live to see the full program and register today. Hello, everyone. This is RheumNow, and we're gonna do a panel discussion on rheumatoid arthritis covering items of interest and conversation from ACR convergence twenty twenty seven. I'm Jack Cush with RheumNow in Dallas, Texas. I'm joined by John Kay at UMass and Artie Cavanaugh at UCSD.
Gentlemen, thank you for joining us. Our format's gonna be a little bit different on this panel. We're gonna do our own little topic themes and then do some discussion. John, why don't you start us off?
Thanks, Jack. It's great to be here and be with you and Arti. I'm gonna talk about cell based therapy. That's a hot topic, especially starting with lupus. Much of the discussion with lupus is all about CAR T cells, and T cell engagers.
I'm going to talk about two abstracts, Abstract nineteen oh two and two thousand three and eighty four. So Abstract nineteen oh two was an oral presentation delivered by Professor David Simon from the Charite in Berlin about the COMPARE trial, a phase one study in which there was a single infusion of CD19 directed CAR T cells in six patients with what was called highly treatment refractory ACPA positive rheumatoid arthritis or difficult to treat rheumatoid arthritis. These patients had had longstanding active disease with a median of six and a half biologic or targeted synthetic DMARDs, and after discontinuation of DMARDs and glucocorticoids, lymphodepletion, and CAR T cell infusion, all six patients experienced clinical improvement, and three maintained drug free remission over the course of the year through week fifty two. The investigators reported quote unquote manageable short term toxicity. All patients developed grade one or two cytokine release syndrome that resolved within three to five days.
No neurotoxicity and no severe infections. Cytopenias were common, and one patient experienced grade three transaminase elevation. The patients experienced profound depletion of CD19 positive B cells in peripheral blood, bone marrow, and synovial tissue that was accompanied by a marked reduction in rheumatoid factor and ACPA with loss of rheumatoid factor and ACPA in four of the six patients. The reduction was 92 to 96% by week fifty two. When B cells reconstituted, the B cells that recovered were predominantly naive and transitional B cells, and there was substantial depletion of memory B cells and plasmablasts.
Antigen experienced TCP reactive B cells were eliminated in all three patients in which this was evaluated, suggesting that disease related autoantibodies are depleted, and the clinical improvement was corroborated by reductions in synovial inflammation by ultrasound, and they also looked at fibroblast activation on FAPI PET imaging. So the conclusions were that CD19 CAR T cell therapy can induce profound immunologic remodeling, perhaps resetting B cell immunity and achieving sustained drug free remission in some patients, but not all. So the responses in this study were heterogeneous, just like in the T cell engagers where patients with rheumatoid arthritis, unlike those with lupus, experience a reduction in disease activity over the first several months, but some experience a recurrence of disease activity that requires use of biologic medications such as abatacept to control disease. Now, some of these patients had previously been unresponsive to the medication that then is used to maintain control of disease. So this is sort of a resetting but not a drug free control inducing therapy.
They planned a randomized phase two comparison with rituximab to see if this is better than rituximab or equivalent. So that is Abstract nineteen oh two about CD19 CAR T cell therapy in highly refractive rheumatoid arthritis. The other abstract is an abstract that was supposedly withdrawn but not withdrawn and was presented. This is Abstract two thousand three and eighty four, which was from Arteva, which just before the ACR meeting announced that they were discontinuing development of their AlloNK therapy. They presented this AlloNK therapy AB101 at EULAR as a late breaker, and it was very positive in terms of their results with rheumatoid arthritis, Sjogren's, and systemic sclerosis.
They experienced improvement in disease activity in the patients treated. Now, this is an off the shelf ALLO NK cell that is derived from cord blood, and the Fc receptor on this ALONK cell is then bound to an antibody, in this case rituximab, and with the rituximab and the ALONK, it depletes B cells. So they experienced profound B cell depletion with B cell reconstitution beginning about six to twelve months after treatment, and like with the CD19 CAR T cell, it was characterized predominantly by naive and transitional B cells. They experienced preservation of serum immunoglobulin concentrations and vaccine antibody titers, so it sounded really good, except they had one patient with Sjogren's disease who developed a fatal grade five leucoencephalopathy approximately ten weeks after treatment with MRI findings that suggested fludarabine associated neurotoxicity, but they can't rule out multifocal progressive leukoencephalopathy, which has been observed with rituximab as well. So, this drug, while potentially effective, was killed by that death experienced in this clinical trial.
So, rituximab with this off the shelf ALONK cell was effective, but the toxicity profile suggested that it wasn't going to be developed further. Now, Novartis and BMS also stopped their CAR T cell programs because of significant toxicity. So, while potentially very effective, the potential toxicity of this cell based therapy approach is not clearly going to be successful for a disease like rheumatoid arthritis, where you can't afford to have severe fatal, reactions.
So there are sort of two, a few messages here that are consistent. One, gee, it's a win, but wait, it's not, But both of them are calling into question the idea of B cell depletion as a therapy in rheumatoid arthritis. I only look at our rheumatology community, how much are you using rituximab by the way? You know? And again, we have a lot of other choices and that's why we don't use a lot of rituximab, but I think some people aren't impressed with rituximab and, you know, we did the clinical trials, we know the drug does work.
It's fine to be where it is, but I think that these studies which have really profound depletion of B cells, have some shortcomings. And that makes me wonder about whether we should be looking forward to cellular targeting therapies in rheumatoid arthritis.
Also from rituximab, and there were a couple of abstracts that really, I think, speak to this issue, the risk benefit. One, 1901 is from Leeds. And remember in Leeds, they've been big proponents of looking at very highly sensitive flow cytometry. Remember, everyone you treat with rituximab depletes their peripheral B cells. But the issue is we're not depleting B cells in the lymphoid organs.
And they would say we're not really completely destroying the peripheral B cells and the plasmablasts, with the treatment. And if what they did is they looked at baseline levels of depletion. And what they found is that the better you depleted, the better you did at five years. So this is treatments and then looking five years later. And the more completely you depleted just with rituximab.
And those who depleted better did better later on. And on the other end, of bookends of this is abstract 2,831. This is from China. And this looked at rituximab in rheumatoid arthritis in the clinic. They had 70 patients, but they had almost 19 infusions each.
And so over time, over the long period of follow-up, which was almost nine years, they have a linear decline in IgG, which you perhaps would have expected. But the strongest association with serious infectious events was low IgG, beyond steroids, beyond comorbid conditions. So yes, the better you deplete, the better you do, but you gotta be careful.
Yeah. So, John, you you looked at that compare trial, was the CAR T... C d nineteen CAR T. When we looked at that, I I was a little concerned about autoantibodies came down, but they came down variably, and responses, you know, were kinda slow whatnot. Maybe they're not getting full depletion.
Again, you're just measuring blood B cell populations. We don't know what's going on in tissues and plasmablasts and whatnot, but what's your take on the clinical responses in those trials?
Well, those trials, the clinical response is good initially, just like you see with biologic or targeted synthetic DMARDs, but the durability of that clinical response by itself is not all that long lasting. The depletion of the autoantibodies, as you point out, reflects what's going on in peripheral blood. They saw deep depletion when they looked at synovial biopsies. But even with deep depletion in the synovium, the durability of response isn't that long. And this is very similar to what Ricardo Grieshopper Boyer observed in the T cell engagers that were published in Nature Medicine out of Erlangen, where there was an initial decrease in disease activity, but then those patients pretty much required some sort of biologic or targeted synthetic DMARC to maintain control of disease.
So these therapies are relatively rapid acting, but not great durability.
So let me just interject another one here that's kind of along the same theme that we're on, and that was, abstract, 09/18 when Professor Pizzalis and his coworkers talked about, synovial biopsies in early RA and looking at five year outcomes. That seventy five patients with early RA who had at least twelve months of follow-up, and looked at them five years later, and they stratified the patients on what they did over the five years, either they were in remission or low disease activity or they were in moderate or high disease activity, forty five and thirty patients respectively. But at baseline, when they did the histology cellular types, it was very clear that the people who did bad had a lot of overexpression of immunoglobulin and humoral immunity, even though these people had early disease. The people who, did the best were in remission or LDA seemed to have more fibroblasts and tissue remodeling markers. The interesting thing to me about that is those are things that we don't target in early disease.
We tend to leave rituximab to, you know, late stage, you know, you know, crashes. And people that, you know, we just have tried as was the case in the COMPARE trial, they had failed six prior DMARDs and biologics at least. So, you know, maybe this this work by Constantine is going to help redesign some of the approach at least to early RA.
Does that Jack, he has a poster every meeting. I love the guy, he's a big proponent of synovial biopsies, it makes total sense that it should be helpful. But these means of gathering data are so robust. You get so much data that you're going to have a story. You're going to absolutely have a story of significance.
And what you do with that, and these conclusions are a little bit different than he had presented previously. His R4RA study looking at synovial biopsies and then trying to say, could you guide therapy toward T cell directed or B cell directed? A word of caution, I think.
I'm sorry, John, maybe we need AI to analyze. What you're right is incredibly, robust, meaning lots of data from which you have to build the story. I like the caution, but I also like the prospective excitement. John?
Well, it's interesting that Koss has also shown that in the difficult to treat rheumatoid arthritis patients, there's a predominance of the fibroblast pathotype. So it's interesting here that early RA, you see a fibroblast predominance that's not addressed in later on. So the drugs that are being developed now, like antibodies to TL1A, address targets that are expressed on fibroblasts. So that's suggesting that the direction of drug therapy really should go, toward the fibroblast, which is really the unmet need in rheumatoid arthritis.
Amen. Amen. Artie, you had, two that excited you.
Well, there's a couple of things. One, the story of clinically suspect arthralgia. We seem to revisit this, at most meetings over the past few years anyway, and it's an important clinical problem. We see these people all the time, don't we? Now that we have gotten our primary care providers and even ER doctors used the idea of checking CCP antibodies, particularly in addition to rheumatoid factor.
You have patients who show up in the clinic whose joints hurt, you don't think that they have synovitis, maybe even look at highly sensitive imaging like ultrasound and MR, and they don't have synovitis, but we know some of them, twenty five-thirty percent of them will go on to develop rheumatoid arthritis. So how do we find those people? Could we possibly treat them that, may end up preventing or at least delaying or perhaps attenuating the rheumatoid arthritis that they develop? Important questions. We still don't have, an absolute answer.
But there are a couple of nice abstracts that looked at this. One was 1832, and I think this should be a teaching slide in, all of our collections. This looked at the military, repository. And of course, when you join the military, you have samples taken of your blood, at various time points. So you have some of the people in the military developed rheumatoid arthritis, and then you can go back and say, at what point did they see or convert?
Did they develop rheumatoid factor and CCP? And as we had seen previously in very similar studies from a similar database, the ANA, here too, we see that the CCP and the rheumatoid factor are start to elevate years before the diagnosis. So, there's something there and that fits with the thing we always say. It's a genetically susceptible host exposed to some, environmental or other influence that then develops the ongoing dynamic, auto inflammatory rheumatoid arthritis. But we just don't know who.
Another abstract, the 1837 looked at what the UR ACR risk stratification. And it's the things that we see in the clinic, including actual morning stiffness, which, you know, your fibro patients are stiff twenty four hours a day, which is not impossible because they're asleep. Grip strength, which we stopped doing, the, swelling and the autoantibodies. And The model is good, but we're still not up to the point where we can use that to say that know which of those patients is going to develop rheumatoid arthritis. Then a follow-up abstract 95, maybe one of the saddest abstracts or saddest bits of research ever because I think we were all hoping it would work and that's the STOP RA study.
Remember that was treating patients who are these clinically suspect arthralgia patients but are CCP positive, treating them with hydroxychloroquine. And as you recall, there was absolutely no difference in the development of rheumatoid arthritis. You could not make a case. You couldn't have cheated and drawn those lines on top of each other any better. So it really had no effect, which was I think incredibly disappointing.
I think we would have loved if a safe medicine like hydroxychloroquine had had some benefit, but this showed that it didn't. This is just a follow-up, actually not new information, but that rheumatoid factor. So remember they had to be CCP positive to get in. But if you throw in rheumatoid factor that really increases the odds that they're going to develop rheumatoid arthritis. But is it enough to actually say that next person you see in clinic tomorrow that you're going to act upon that remembering all the old studies that we have had with abatacept quite a number of studies with rituximab with methotrexate had to stop RA with hydroxychloroquine.
Still an important topic and still unresolved.
Arty, you bring up some very interesting points. That study from the US military serum repository, I recall that they also identified antibodies to PAD one and PAD four, which are peptidyl arginine deaminase. PAD four is involved in citrullination as is PAD one. PAD two is involved in the generation of TNF. So it's interesting that they're also developing antibodies against the enzyme that's involved in citrullination.
I don't know what that means, but interesting. The other point that you bring up about the EULAR criteria with measuring grip strength, those are sort of an expansion of the CARE tool, which was developed in Leiden by Annette Vanderhelm Van Miele, where they came up with a score, I think seven questions and a score of four was the cutoff, that suggested that patients had high likelihood of progressing to early inflammatory arthritis. Not to be self serving, but I'd like to point out my colleague, Karen Salomon Escoto, who had a poster at EULAR where she validated the CARE tool in The United States and came up with exactly the same cutoff of four. So that could be used to prioritize patients who have clinically significant arthralgia to give them an earlier appointment than they would normally get since rheumatology clinic schedules are quite full and enhance the ability of those patients to be seen early and initiated on appropriate therapy. And at this meeting, Abstract fourteen forty six, Karen presented the use of Squeeze Egg, Squeg, which is a device that's commercially available, costs about $100 It's Bluetooth enabled and FDA approved to measure grip strength.
And it transmits the grip strength to an app on the iPhone, and you can record it in the clinic note. And so there's a way of measuring the grip strength other than just pumping up a sphygomanometer slightly. And it's quite useful to detect deteriorations in how a patient is doing in between visits if they do this remotely or between visits if you do it when you see the patient.
Yeah, in RheumNow, I think this is called a mulligan, Jonathan, when you reference your own work. So you get one, so you took it nicely done, nicely played.
I like it. Autoantibody chronology and the slide of that where it grows really over twenty years, not even ten, It is still spearheaded by CCP. CCP is the earliest, the strongest and whatnot. As you get closer and closer to time point zero when they develop RA is when they get this greater multiplicity. To me, reinforces that model of autoimmunity starts, there's epitope spreading, there's this multiplicity of autoantibodies.
It is many autoantibodies at the time of disease onset, and we know that having multiple autoantibodies is itself a risk factor. Now, don't know if it's a chicken or the egg there, that the antibodies themselves are the causative factor or what's driving autoantibodies, but it really conforms very well to the story and like Hardy says, it becomes a great teaching tool. Then the other thing I'd say about UR score is that it validates and the score of your colleague, John, validates what Kevin Dean said a long time ago. Is it CSA and you just got to watch it or is it RA and you need to treat it? And it's a ratcheting effect.
The more things they've got that make you think, oh, this is looking more and more like RA beyond the CCP and a positive family history, the more you can step in and, you know, give me your best shot and, play Pat Benatar over and over again, maybe with the hope of helping some. But we do have data on on what we should use and when we should use it. But
still So, Jack, along those lines, because I find to the patients, the CSA patients, it's a hard sell to offer the medicines for disease they may never develop. But I bet you, and I haven't really done this yet, but I might have to, is that they're open to turmeric. They're open to Mediterranean diet. They're open to weight loss. Maybe that's the time, at that time...
Maybe you can still influence the disease, and the way to do it is not by medicines, but by lifestyle.
So it's basically, it's fad, DTC and television, and fear are the motivating factors as to whether or not they might want a therapy. Let me move on because we want to wrap this up. There was a plenary session that was, I think, interesting. It was a small study out of Duke. Hannah McClellan and colleagues abstract twenty eight zero three immunologic and clinical benefits of lifestyle, remodeling on an aging immune system in RA.
They took 20 RA patients, and they did this pilot trial where they were, sedentary, at least overweight, if not obese. BMIs of twenty eight to forty, and they either were randomized. Everyone got some sort of counseling. And then the... And and the sweat group, the SWET group got intensive, exercise training and lifestyle counseling more than the chat observation group.
And when they looked at them, I think the time point was twelve or sixteen weeks later that, yes, both groups got better with improvement in their DAS CRP, which improved by fourteen percent and patient global swollen joints improved by thirty six percent. But the sweat group, the, lifestyle intervention with diet and exercise, exercise being a 115 week. They found out it was actually even less that that was even effective. They had cellular changes with significant changes in Tregs, NK cells, memory t four cells that were interesting. And while that was going on, the patient also had improvement in strength and mobility and function.
But what didn't improve was cytokine profiles, sed rate and CRP. You'd think this bland population of older people who are obese, and that what am I gonna do for them? This kind of research suggests that, lifestyle changes can do a lot for them and I found that surprising. I really thought that, I'd like to see where they go with this. That might be even more interesting.
The other thing that kinda fits in with lifestyle was another plenary from, presented by Nicholas McCormack, representing the RISE registry. This is abstract o eight six seven showing that when GLP-one, agents were used in RA and PSA, and they specifically looked at patients starting semaglutide and tirzepatide, that they had significant weight loss. I think it was like 15 pounds. In general, 15.6 pounds, and 58, 54% loss greater than 5% of their body weight. We know from psoriasis studies that losing at least 5% will give you clinical benefits.
10 of 10% great benefits. 20% wow. But that this drop in weight was associated with a drop in rapid three scores. For every, I think, 5%, you drop your rapid three by, like, one point or whatever. So it was kind of a positive report about GLP one and inflammatory arthritis, RANPSA.
But it was kind of on the mild side because an abstract presented effort was the study that, Philip Conahan presented that was just dramatic. You know, these people had lost 71 pounds and had dramatic improvement, clinically. So the question is, do you need to lose more weight? Is or maybe RA isn't the great subject here for, triple agonist interventions with incretin therapy as it is in PSA and in OA. I think that those two abstracts were very contrasting.
John, I know you want to talk about this. What's your thought?
It was interesting that in that abstract from the RISE registry, after the presentation, there was a question about swollen and tender joints, and there was no significant improvement in swollen or tender joint count, which doesn't quite support the efficacy of GLP-one therapy in rheumatoid arthritis. There were a whole bunch of TriNetX analyses where someone can just call up the data in an hour, get an abstract, which one suggested that PSA was better than RA for GLP one response. There's no question that weight loss is beneficial and exercise is beneficial. John Varga mentioned he thinks that aging is the key to all rheumatologic diseases. So looking at the biology of aging, maybe advanced glycation end product formation, which plays a role in a number of processes in collagen.
Getting back to GLP-1s, certainly they're beneficial in many, many, many ways. Anti inflammatory effects are just but one. They act on the central nervous system. Anecdotally, I've found that my patients who are on GLP-one therapy are more pleasant and easier to deal with once they're on them. They seem happier.
So other than the cost, there seems to be little downside, the rare eye complications. But it looks as if probably a third of the population is taking these and the other two third would if they could afford them.
Old joke, the, guy goes... They said, boy, what's up? Said, well, I went to the doctor. He said, you know, you eat less, don't drink, don't smoke, don't chase women, start exercising, lose weight, and you live an extra year. Said, So I did it.
It was the most miserable year of my life.
Exactly.
Well, know what? I want to end this session with a story And, many of you know and some of you look forward to the end of every ACR where Artie Cavanaugh and I, do Rheumatology Roundup. And we've been doing that for about twenty years, but the originator of Rheumatology Roundup was Jonathan Kay. John, how did you get us on the map with this gig?
I was chair of education at the time, and we were discussing how best to end the meeting, and we were inspired by CARTAL, click and clack. And we found that the... Or felt that the rapport between you and Arty was similar to that between Tom and Ray Maliatsi. And we suggested this as a session based on a tape that was sent in, and it was incredibly successful. And it persisted for a number of years.
Although, this year, I just tuned into the RoomNow podcast and heard the beginning of an hour long discussion between you and Artie doing a a version of that rheumatology roundup, which wasn't at the meeting, but is immortalized for all of us to listen to during our commute.
Yeah. The ACR decided to go a different way about five years ago, but there are still people that are stopping Arty and I on the last day and saying, I'm coming to your session. What time does it begin? And it's sort of like, well, you're gonna have to tune in on your podcast channel. So anyway, I wanna thank Arty and John for a great discussion and covering, what is always an interesting area at ACR, rheumatoid arthritis.
Tune in for more topic panels. Bye, everyone. Bye bye.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.